Assembly Bio Closes $115M Public Offering, Including Full Underwriter Option Exercise
ASMB has more than doubled off its 52-week low of $13.13 on elevated volume (2.1× avg).
Summary
Assembly Biosciences completed a significant $115 million public offering of common stock and pre-funded warrants, including the full exercise of the underwriters' option, to fund its clinical development and operations.
Key Events · Financing and Capital Events · ASMB
-
Offering Closed
The company closed an underwritten public offering on May 26, 2026, raising approximately $107.4 million in net proceeds.
-
Underwriter Option Fully Exercised
The underwriters fully exercised their 30-day option to purchase an additional 566,040 shares of common stock, indicating strong demand.
-
Securities Issued
The offering included 3,358,602 shares of common stock and pre-funded warrants to purchase up to 415,000 shares of common stock.
-
Pricing Details
Common stock was offered at $26.50 per share, and pre-funded warrants at $26.499, representing a modest discount to the current market price.
Analysis · ASMB · Life Sciences
Assembly Biosciences successfully closed a public offering, raising approximately $107.4 million in net proceeds. This capital raise, which includes the full exercise of the underwriters' option for additional shares, is substantial relative to the company's market capitalization. While dilutive for existing shareholders, the proceeds are critical for funding the clinical development of pipeline candidates and general corporate purposes, extending the company's cash runway. The participation of institutional investors and the full exercise of the option indicate market confidence in the company's prospects despite the dilution.
At the time of this filing, ASMB was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $456.9M. The 52-week trading range was $13.13 to $39.71. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.